oncology
GI

Olaparib delays metastatic pancreatic cancer progression in BRCA carriers


Adding a PARP inhibitor to standard therapy for metastatic pancreatic cancer can achieve substantially better outcomes for a small subgroup of patients with BRCA germline mutations, according to results presented at ASCO 2019. Data from the POLO trial suggest that olaparib maintenance treatment after platinum-based chemotherapy should be the new standard of care for patients ...

Already a member?

Login to keep reading.


OR
© 2019 the limbic